Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Apellis Pharmaceuticals, Inc. - Common Stock (NQ:APLS)

26.34 +2.40 (+10.03%)
Streaming Delayed Price Updated: 3:37 PM EST, Jan 7, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Headline News about Apellis Pharmaceuticals, Inc. - Common Stock

< Previous 1 2 3 4 5 6 7 8 9
...
12 13 Next >
News headline image
12 Health Care Stocks Moving In Thursday's Intraday Session ↗
 
Via Benzinga
News headline image
Why Is Apellis Pharmaceuticals Stock Trading Lower Today? ↗
Apellis Pharmaceuticals Inc (NASDAQ: APLS) announced an update on the ongoing review of its marketing application for intravitreal pegcetacoplan for geographic atrophy (GA) secondary to age-related... 
Via Benzinga
News headline image
Apellis Crashes As Likely European Rejection Looms For Eye Drug Syfovre ↗
The treatment, Syfovre, has faced numerous safety concerns in the U.S., where it's approved. 
Via Investor's Business Daily
News headline image
12 Health Care Stocks Moving In Thursday's Pre-Market Session ↗
 
Via Benzinga
News headline image
Why bluebird bio Shares Are Trading Higher? Here Are Other Stocks Moving In Monday's Mid-Day Session ↗
Shares of bluebird bio, Inc. (NASDAQ: BLUE) rose sharply during Monday’s session after the company presented updated data from its gene therapy program in transfusion-dependent beta-thalassemia at the... 
Via Benzinga
News headline image
Coinbase, Riot Platforms, Marathon Digital And Other Big Stocks Moving Lower On Monday ↗
U.S. stocks traded mostly mixed, with the Dow Jones index gaining more than 100 points on Monday. Here are some other big stocks recording losses in today’s session. 
Via Benzinga
Topics Stocks
News headline image
Apellis Pharmaceuticals Upgraded To Buy: Analyst Sees Potential In Syfovre's Strong Launch ↗
BofA Securities analyst Tazeen Ahmad upgraded Apellis Pharmaceuticals, Inc. (NASDAQ: APLS) to Buy from Neutral,  
Via Benzinga
News headline image
14 Analysts Have This to Say About Apellis Pharmaceuticals ↗
 
Via Benzinga
News headline image
Block To Rally Around 54%? Here Are 10 Top Analyst Forecasts For Tuesday ↗
Top Wall Street analysts changed their outlook on these top names. For a complete view of all analyst rating changes, including upgrades and downgrades, please see our analyst ratings page. 
Via Benzinga
News headline image
Why Is Apellis Pharmaceuticals Stock Trading Lower Today? ↗
Shares of Apellis Pharmaceuticals Inc (NASDAQ: APLS) declined following a  
Via Benzinga
News headline image
21 Analysts Have This to Say About Apellis Pharmaceuticals ↗
 
Via Benzinga
News headline image
Analyst Ratings for Apellis Pharmaceuticals ↗
 
Via Benzinga
News headline image
Why Apellis Pharmaceuticals Stock Popped Today ↗
Apellis Pharmaceuticals, Inc. (NASDAQ: APLS) shares are trading higher Thursday after the company reported preliminary U.S. 
Via Benzinga
News headline image
Magnificent 7 Take Center Stage In Hedge Fund Portfolios: Analysts Warn Of Extreme Concentration ↗
Hedge fund portfolios are intensifying their focus on technology stocks, with holdings in mega-cap tech reaching record levels. 
Via Benzinga
News headline image
Inside Cathie Wood’s Portfolio: 3 Stocks She Is Betting Millions On ↗
Are you looking to invest in disrupting stocks like Cathie Woods? Here are three stocks Cathie Wood is betting millions on. 
Via InvestorPlace
News headline image
10 Health Care Stocks Whale Activity In Today's Session ↗
 
Via Benzinga
News headline image
Apellis Pharmaceuticals Stock Improves With An RS Ratings Over 90 ↗
Apellis Pharmaceuticals shows improving price performance, earning an upgrade to its IBD Relative Strength Rating. 
Via Investor's Business Daily
News headline image
Why Shares of Apellis Pharmaceuticals Were Down Wednesday ↗
A short-seller report sent the stock tumbling. 
Via The Motley Fool
News headline image
Analyst Ratings for Apellis Pharmaceuticals ↗
 
Via Benzinga
News headline image
Apellis Pharmaceuticals Stock Shows Rising Relative Strength ↗
A Relative Strength Rating upgrade for Apellis Pharmaceuticals shows improving technical performance. Will it continue? 
Via Investor's Business Daily
News headline image
10 Health Care Stocks Whale Activity In Today's Session ↗
 
Via Benzinga
News headline image
Stocks Mixed Amid Earnings, Consumer Sentiment Data ↗
Stocks are mixed this afternoon, as investors unpack earnings reports from several bank giants as well as economic data. 
Via Talk Markets
News headline image
JPMorgan, Wells Fargo, Citigroup And Other Big Stocks Moving Higher On Friday ↗
U.S. stocks traded mostly higher, with the Dow Jones gaining more than 100 points on Friday. Here are some big stocks recording gains in today’s session. 
Via Benzinga
Topics Stocks
News headline image
Benzinga's Top Ratings Upgrades, Downgrades For October 6, 2023 ↗
 
Via Benzinga
News headline image
Why Pioneer Natural Resources Shares Are Bouncing By Around 12%; Here Are 20 Stocks Moving Premarket ↗
Gainers Vaccinex, Inc. (NASDAQ: VCNX) shares rose 40.2% to $1.15 in pre-market trading as two large insider buys were reported after the close on Thursday. 
Via Benzinga
News headline image
Constellation Brands To Rally Over 20%? Here Are 10 Other Analyst Forecasts For Friday ↗
HSBC raised the price target for Constellation Brands, Inc. (NYSE: STZ) from $280 to $290. HSBC analyst Carlos Laboy maintained a Buy rating. Constellation shares fell 3.2% to close at $241.33 on... 
Via Benzinga
News headline image
Why Sharps Technology Shares Are Trading Lower By Around 32%? Here Are Other Stocks Moving In Wednesday's Mid-Day Session ↗
Gainers 
Via Benzinga
News headline image
Unity Software To Rally Around 60%? Here Are 10 Other Analyst Forecasts For Friday ↗
B of A Securities raised the price target for Unity Software Inc. (NYSE: U) from $46 to $56. B of A Securities analyst Ryan Gee upgraded the stock from Neutral to Buy. Unity Software shares fell 3% to... 
Via Benzinga
News headline image
Benzinga's Top Ratings Upgrades, Downgrades For September 15, 2023 ↗
 
Via Benzinga
News headline image
Why Is Apellis Pharmaceuticals Stock Trading Lower Today? ↗
Apellis Pharmaceuticals Inc (NASDAQ: APLS) revealed a comprehensive corporate restructuring plan aimed at catalyzing the growth of its flagship products, Syfovre (pegcetacoplan injection) and  
Via Benzinga
< Previous 1 2 3 4 5 6 7 8 9
...
12 13 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.